Jazz Pharmaceuticals is a biopharmaceutical company that develops and commercializes medicines across neuroscience, oncology and other serious diseases. It operates internationally and is headquartered in Dublin, Ireland.
Artios added six senior leaders in 2026 as alnodesertib moved toward late-stage development and potential U.S. commercialization. The company is also running a Phase 2 study of ART6043.
Wafik S. El-Deiry highlighted p53 research and the August 2025 approval of dordaviprone/modeyso, the first treatment for diffuse gliomas with H3K27M mutations. Separate posts also described glioblastoma precision oncology discussions and a lifetime achievement award in Mumbai.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
The cardiovascular biologics market is projected to reach $4.23 billion by 2033, while the cell therapy market is expected to reach $5.38 billion by 2032, driven by RNA-based therapies and regulatory approvals.
The Consolidated Appropriations Act of 2026 extends the FDA's authority to award rare pediatric disease priority review vouchers through September 30, 2029, restoring a key incentive for developing therapies for rare pediatric diseases.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07533942 |
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07459634 |
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07434973 |
Stratification and Treatment in Early Psychosis Study - PROMOTE |
NOT_YET_RECRUITING | PHASE3 |
| NCT07377539 |
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants |
RECRUITING | PHASE1 |
| NCT07290985 |
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas |
NOT_YET_RECRUITING | PHASE2 |
| NCT07282587 |
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma |
RECRUITING | PHASE2 |
| NCT07278505 |
Study of Cannabidiol and Neuroimaging on Stress |
RECRUITING | PHASE1/PHASE2 |
| NCT07233239 |
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures |
RECRUITING | PHASE1 |
| NCT07192068 |
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene. |
RECRUITING | PHASE2 |
| NCT07176312 |
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients |
RECRUITING | PHASE2 |
